Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Olumuyiwa Adeboye

Hospice and Palliative Medicine Lagrange, GA Medical Doctor

NPI 1720261407 CMS profile 1209357

111 Medical Dr, Lagrange, GA 30240

Open in the dashboard

General payments

$2,367

119 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Olumuyiwa Adeboye of Lagrange, GA is reported in the CMS Open Payments database as having received $2,367 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Hospice and Palliative Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $972 50
2024 General $956 47
2023 General $352 17
2022 General $87 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Olumuyiwa Adeboye
  • Hospice and Palliative Medicine median
  • Middle half of Hospice and Palliative Medicine
  • National median

In program year 2025, general payments to Olumuyiwa Adeboye were reported at $972. Among 378 Hospice and Palliative Medicine profiles paid that year, the median was $78 and the middle half received between $28 and $160.

Show as a table
Year Olumuyiwa Adeboye Hospice and Palliative Medicine median Middle half National median
2019 $0 $80 $22–$147 $163
2020 $0 $36 $18–$121 $114
2021 $0 $64 $23–$194 $132
2022 $87 $67 $22–$158 $149
2023 $352 $65 $25–$149 $160
2024 $956 $75 $25–$158 $164
2025 $972 $78 $28–$160 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Merck Sharp & Dohme Corporation $243 12 payments
  2. Daiichi Sankyo Inc. $228 11 payments
  3. Novartis Pharmaceuticals Corporation $205 9 payments
  4. AstraZeneca Pharmaceuticals LP $126 7 payments
  5. Pfizer Inc. $112 6 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $110 5 payments
  7. Janssen Biotech, Inc. $103 6 payments
  8. Jazz Pharmaceuticals Inc. $87 4 payments
  9. Sobi, Inc $80 4 payments
  10. Eisai Inc. $67 4 payments
  11. Other $1,007 51 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,336 118 payments
  2. Education $31 1 payment
Products named General payments · program years 2022–2025
  1. KEYTRUDA $243 12 payments
  2. ENHERTU $212 10 payments
  3. KISQALI $96 4 payments
  4. ZEPZELCA $87 4 payments
  5. LYNPARZA $77 4 payments
  6. IBRANCE $75 4 payments
  7. NINLARO $67 3 payments
  8. Lenvima $67 4 payments
  9. PLUVICTO $61 3 payments
  10. Fabhalta $48 2 payments
  11. Other $1,708 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

859

Median for Hospice and Palliative Care: 260

Drug cost

$13,096

Median for Hospice and Palliative Care: $10,445

Branded share of claims

25%

Median for Hospice and Palliative Care: 16.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fentanyl Generic 22 $2,187
Sucralfate Generic 14 $1,301
Morphine Sulfate Generic 53 $1,201
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 66 $1,004
Oxycodone Hcl Generic 50 $887
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 55 $714
Venlafaxine Hcl Er Venlafaxine Hcl Brand 17 $585
Hydromorphone Hcl Generic 28 $529
Morphine Sulfate Er Morphine Sulfate Brand 22 $521
Ondansetron Hcl Generic 36 $440

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,124 Part D prescribers listed as Hospice and Palliative Care; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$13,263

Medicare's payments for the services billed

Medicare patients

58

Average age 76

Services billed

131

39 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 74%
Arthritis 67%
Ischemic heart disease 57%
Cancer 53%
Chronic kidney disease 52%
Heart failure 45%
COPD 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $78
$78 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $62
$62 — —
KISQALI
  • Novartis Pharmaceuticals Corporation $50
$50 — —
Fabhalta
  • Novartis Pharmaceuticals Corporation $48
$48 — —
NINLARO
  • Takeda Pharmaceuticals U.S.A., Inc. $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospice and Palliative Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record